Advertisement

Topics

Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association

09:21 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspa...

Other Sources for this Article

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
Matt Fearer, 617-301-9557
Director, Corporate Communications

NEXT ARTICLE

More From BioPortfolio on "Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...